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AS1-1  Introduction : promotion of 
open innovation for drug innovation
Akinori Akaike1,2
1Dept. Cell. Pharmacol., Grad. Sch. Pharm. Sci., Nagoya Univ., 2Dept. 
Pharmacol., Grad. Sch. Pharm. Sci., Kyoto Univ.
Drug innovation aiming to solutions for unmet medical 
needs is one of the most important issues in Japan 
reaching a highly aging society. Exchange of ideas between 
researchers across walls of organizations will contribute to 
the achievement of the discovery of the new type of drugs. It 
is widely recognized that the promotion of open innovation 
for drug innovation provides a platform for idea-sharing and 
lowers the barrier for collaborations among researchers in 
basic and clinical À elds in universities and drug industries. 
The participation of government officers in regulatory 
science is also important in accelerating the achievement 
of the drug innovation. In this symposium, 5 speakers will 
present the situation of the open innovation drug discovery 
and regenerative medicine of Japan and USA. Latter 
part of my presentation will be focused on the activity 
of Consortium for Drug Innovation in the Tokai Region 
(CDIT) as an example of the pipeline construction between 
universities and drug industries. The activity of CDIT 
focuses in the matching of the needs of the drug industries 
and research results of the universities. Those activities will 
greatly support the development of innovative drugs and 
medicine.
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AS1-3  Current status and issues of 
pharmaceutical development in Japan: 
Toward healthy social security fi nances 
and pharmaceutical industry growth
Yoshihide Esaki
Director Bio-industry Division, Ministry of Economy, Trade and Industry
Advances in regulatory science are increasingly causing 
difficulties for the development of new drugs, not only in 
Japan but globally. These changes in the environment 
for drug discovery, however, have also provided Japanese 
pharmaceutical companies, which have previously lagged 
behind in the race to develop antibody drugs and other 
bio-medicines, with a chance to catch up. Promotion of 
personalized medicine will be the key, and to achieve this 
will require not only the transformation of the business 
models used by pharmaceutical companies but also 
the review of the approval process for new drugs. Such 
initiatives will both give Japan the advantage in the clinical 
trial environment, where the high costs caused by rigorous 
quality control are recognized to be issue currently, and 
make it easier for pharmaceutical companies to approach 
academic startups, and may also help to promote open 
innovation in Japan.
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mS12AS1-2  Trend on open innovation for 
rug discovery research
ayoi Sasaki
apan Health Sciences Foundation
apan Health Sciences Foundation(JHSF) is advancing 
esearch and survey project on various topics relating 
o drug discovery research based on advanced and basic 
ciences and technology, the medical needs, the future 
rends of the disease and medical treatment, etc., since 1986 
f JHSF establishment. The overseas survey report which is 
nvestigating the drug discovery strategy and technology of 
verseas pharmaceutical companies introduced outsourcing 
n various stages of drug discovery several years before.
fter the open innovation was advocated, about ten years 
ave passed. The measure in the national pharmaceutical 
ompanies recently followed the open innovation as 
utsourcing of search of drug discovery. The trend in and 
utside the country was adjusted in the report ‘Open 
nnovation for drug discovery - use of the research resource 
y external cooperation-’, research resource committee’s 
eport in the 2012 À scal year. At this symposium, the trend 
n open innovation for drug discovery would be summarized.
AS1-4  Acceleration of open 
nnovation from the standpoint of start-
p company
aoki Tani
aQualia Pharma Inc.
aQualia Pharma Inc., a spinout from Pfizer Inc.’s Japan 
esearch operation, is a research and development-based 
harmaceutical company in Aichi prefecture and began 
ts operation in July 2008. At present, RaQualia’s primary 
mphasis is on pain and gastrointestinal disease areas 
argeting ion channels. From the beginning of its operation, 
aQualia firmly believes that innovation will be achieved 
ia open collaboration with academia and private sectors. 
ur knowledge gained from broad experiences will enable 
mplementation of a transcendent collaboration network 
hat leaps industry barriers and serves as the driving force 
or effective and efÀ cient research and development of new 
rugs. Against this background, we have made a strategic 
ecision to relocate the discovery functions of the company 
o Nagoya University, expecting that further synergy effect 
ith academia will be achieved. RaQualia and Nagoya 
niversity established a division of analytical study on 
fficacy pharmacology in February 2014. They will jointly 
ork to identify innovative drug candidates, combining 
aQualia’s drug discovery expertise and Nagoya University’s 
cademic research capabilities. Open collaboration and 
rust are vital components to our strength and our business 
odel.
AS1-5  Southern California 
Biocluster’s history, characteristics and 
its open innovation
Jiro Fujita
Biocom Japan Consulting
California’s economic activities in life science have reached 
to $259 billion, and  Southern California alone employs 
110,000 people. And, the center of the Southern California 
Life Science lies in San Diego.  San Diego is 3rd largest life 
science cluster in the world. 30 years ago, it all started with 
one local life science company’s success  and a cluster of 
research institutes. This cluster is still growing. There are 
three strong DNAs of San Diego: 1) Collaborative between 
individuals and organization, 2)It welcomes newcomers, 
and 3)It embraces risk and perseverance. Also, the trade 
and nonprofit groups were created to bring together 
entrepreneurs, researchers, investors and anyone who can 
support their goals. The most representative of those groups 
is Biocom, which was strongly involved in this cluster’s 
growth. Biocom offers member companies meaningful access 
to the influential drivers propelling the industry forward 
across all major life science sectors. Biocom provides a 
tremendous range of initiatives and programs in public 
policy, capital development, group savings, professional 
network building and talent development. All the above 
factors provide a À tting ground for an open innovation.
AS2-2  Strategy of research and 
development of drugs in Japan
Ryozo Nagai
Jichi Med. Univ.
It has been a social concern that the number of newly 
developed drugs is lately decreasing in Japan.  Considering 
this situation, the Japanese government has recently 
founded Japan Agency for  Medical  Research and 
Development (A-MED) to promote R &D of drugs in 
Japan and enhance the international competitiveness. 
For the moment the A-MED focuses on those projects, 
such as development of drugs and medical apparatuses, 
evidence-based medicine, information and communication 
technology, genome medicine, regeneration medicine and 
genome medicine, thus aiming at linking of basic science 
to innovation.  However, development of drugs or medical 
apparatuses are through a cycle including basic researches, 
translational research, practice in clinical settings and 
evaluation in community.  Current clinical studies must 
be performed in compliance with different requirements. 
Any study using human subjects must be examined for 
ethical validity, safety and toxicity in advance.  In addition, 
requirements for patient consent and protection of personal 
information as well as IRBs, GMP for pharmaceutical 
manufacturing and quality control, GLP for safety studies 
on pharmaceutical products and GCP for clinical studies 
are involved in the studies.  Therefore, the importance of 
regulatory science is highly publicized to review the existing 
regulatory regime of pharmaceuticals among industry, 
academia and government with the participation of patients 
and the public.  In the symposium, important issues to be 
solved for R&D of drugs in Japan will be presented.S1AS2-1  Purposes of act on 
promotion of healthcare policy and 
Japan agency for medical research and 
development (AMED)
Toshio Miyata1,2
1Health and Global Policy Institute, 2Cabinet Secretariat, Offi  ce of HealthCare 
Policy
Japan is becoming an ultra-aging society. It is important to 
extend the health expectancy in order to establish a society 
in which people enjoy long and healthy lives. Japanese 
government fosters pharmaceutical and medical device 
industries that can contribute to Japan’s economic growth 
and global public health by the third arrow of “Abenomics 
“. Two acts, act on promotion of healthcare policy and act 
on the independent administrative agency for medical 
research and development, were passed in 2014. AMED 
(Japan Agency for medical research and development) will 
ensure the most suitable research funds for researchers 
in academia or hospitals consistently corresponding to the 
progress of their translational or clinical research from April 
2015.
AS2-3  Advanced activities of the 
pharmaceuticals and medical devices 
agency (PMDA)
Tetsuo Nagano
Pharmaceuticals and Medical Devices Agency (PMDA)
First of all, I would like to introduce the mission of the 
Pharmaceuticals and Medical Devices Agency (PMDA), 
which is to improve the public health and safety of our 
nation by reviewing applications for marketing approval 
of pharmaceuticals and medical devices (product reviews), 
conducting safety measures (safety measures), and 
providing relief to people who have suffered from adverse 
drug reactions (relief services for adverse health effects). 
This is so-called “safety triangle” system, which contributes 
to public health. Under this system, the PMDA is committed 
to fulfilling its responsibilities in line with its philosophy, 
which was developed by all its employees. Secondly, I will 
mention Pharmaceutical Affairs Consultation on R&D 
Strategy for academia and venture companies, which are 
not familiar with actual drug development. There are so-
called death valleys between the basic research and the 
production of drugs. These death valleys include shortage 
of À nancial budget, lack of knowledge on regulatory system 
and developmental strategies. To overcome these issues, 
PMDA started this Consultation on R&D Strategy in July 
2011. Finally, I refer to the Science Board, which the PMDA 
established on May 14th 2012 as a high-level consultative 
body which discusses scientific aspects of pharmaceuticals 
and medical devices review.3
AS2-4  Role of pharmacology in 
promotion strategy of medical research 
and development
Toru Kawanishi
National Institute of Health Sciences
For Japan becoming an ultra-aging society, the development 
of advanced medical technologies is anticipated for 
establishment of a society in which people enjoy long and 
healthy lives.  Therefore, at present the nation’s policy for 
R&D promotion of medical products including innovative 
pharmaceuticals and  improvement of R&D environments, 
is formulated.  Here, the roles of pharmacology in R&D of 
cutting-edge pharmaceuticals are presented and discussed. 
Historically, pharmacology has played important roles 
for development of many drugs, because its main areas 
are pharmacodynamics and pharmacokinetics, which are 
indispensable for their development. Recently, in Drug-
Discovery Process there is a tendency that Target-centered 
Drug Design substitutes for Compound-centered Drug 
Design.  However, in Drug-Development Process, analysis 
data of pharmacological effects, which are directly linked 
to the clinical endpoint, are needed for the evaluation of 
candidate products based on evidence-based medicine. 
Especially, in the development of species-speciÀ c and target-
specific pharmaceuticals, such as antibody drugs and 
oligonucleotide drugs, it is important to develop method for 
quantitative measure of pharmacological effects and analyze 
them. Pharmacologist would be anticipated to play main 
roles in such kind of analysis.
AS3-2  Regulatory science for new 
drug development and pharmacological 
research: Industry perspective
Kazumichi Kobayashi
OPIR, JPMA
In recent years, new drug development has become more and 
more complicated, and there is more and more demand for 
the improvement of efÀ ciency. In this regard, globalization 
and strategic characteristics of new drug development are 
the most important factors. Under such circumstances, to 
what extent are the roles of pharmacological researchers 
in new drug development understood by people in other 
sections? In this session, a speaker from outside the field 
of pharmacological research presents his attitudes toward 
pharmacological researchers, based on his experiences 
establishing and assessing development strategies and 
business plans.The speaker thinks that the exploratory 
stage and the development stage are totally different. In 
the former case, it is understood that pharmacological 
research plays a leading role and serendipity is prioritized. 
In contrast, in the development stage, evaluation of drugs, 
especially for clinical evaluation, plays a leading role. In 
this session, the role of pharmacological research in the 
development stage is classiÀ ed into several categories, and 
the speaker presents some points that pharmacological 
researchers are expected to recognize at the stage where 
R&D strategies and business plans are discussed.SAS3-1  Pharmacology and 
regulatory science foresee drug 
development
Katsura Tsukamoto
Global Regulatory Science, Gifu Pharmaceutical Univ.
Regulatory science is the way of scientific thinking which 
helps us to make the best choice for society, by judging 
the benefits and risks of drugs using various information 
sources. This is the key for establishing evaluation 
standards in drug development and approval. The drug 
development environment is always moving, and the 
evaluation standard changes often by imputing new 
information. Therefore we should adapt, prospect and create 
changes of the evaluation standard using regulatory science. 
Pharmacology is one of essentials to improve efficacy 
and safety of drugs. It should improve drug development 
corresponding to rapidly-advancing science and technology. 
Non-clinical pharmacology must endorse clinical efficacy 
and safety in accordance with recent scientiÀ c level as well 
as following regulations. The evaluation should be done 
by up-dated standards using the advantage of non-clinical 
models what is not possible in clinical models. Therefore it 
is important that pharmacologists should well understand 
regulatory science, because the evaluation standards, 
including guidance and guidelines, will be adopted and 
improved based on this regulatory science. I believe that 
drug development will become more efficient if regulatory 
science is adopted into pharmacology.
AS3-3  Approaches for promoting 
regulatory science in PMDA
Rumiko Hosoki
Regulatory Science Division, Offi  ce of Regulatory Science, Pharmaceuticals 
and Medical Devices Agency (PMDA)
In order to lead promptly to utilization the innovative seeds 
obtained from basic research, it is required to promote 
regulatory science (RS).  Mid-term targets and plan of the 
Pharmaceuticals and Medical Devices Agency (PMDA) 
from FY2014 to FY20181, 2 have been established, and 
PMDA shall provide support to be the À rst in the world to 
facilitate practical use of innovative drugs etc. and promote 
RS and globalization.  Furthermore, through performing 
RS research, PMDA shall train human resources to be 
experts in it.  Therefore, I will introduce our approaches 
for promoting RS in PMDA, such as “the Science Board 
which was comprised from external experts”, “RS research 
performed by PMDA personnel”, “the joint graduate school 
program” and “the Human Resource Exchange Program for 
developing innovative drugs, medical devices and cellular 
& tissue-based products”.  Moreover, I will explained that it 
is necessary to cooperate between industry, academia and 
government.Reference1 Mid-term Targets of the PMDA, 
Instruction No. 0307-73, Dated March 7, 20142 Mid-term 
Plan of the PMDA, NotiÀ cation No. 0331-44, Dated March 
31, 201414
AS3-4  Roles of regulatory science 
on review and safety assessment of 
new drugs
Yoshiaki Uyama
Pharmaceuticals and Medical Devices Agency
Every year, more than hundred new drugs are approved in 
Japan, but all of them have some scientific uncertainty in 
terms of efficacy and safety at the time of drug approval. 
These uncertainties could usually be due to immature/
unsolved sciences and limited feasibility/cost. Regulatory 
science, here, should play a role to minimize the uncertainty 
through improvement on methods/tools of data collection 
and evaluation. One of examples is how to evaluate 
impacts of ethnic factors on drug efficacy and safety 
when extrapolating foreign population data to Japanese 
population in regulatory review. It is also important that a 
decision based on regulatory science should be acceptable 
by society as well as patients. In this presentation, how 
regulatory science is applied for regulatory decision on 
review and safety assessment of new drugs will be presented 
with some examples. A better understanding of Regulatory 
Science in the field of pharmacology will contribute to 
increasing efficiency of drug development and providing a 
better drug to patients.S1AS3-5  Regulatory science plays 
an important role in the global 
development of new drugs
Masahiro Tohkin
Dept. Reg. Sci., Nagoya City Univ. Pharma. Sci.
Global development of new drug has been recognized as 
powerful tools for solving the drug lag in Japan. However, 
the ethnic differences are one of the most important factors 
in the global development. Recent report suggested that 
the global clinical trials (GCT) conducted in East Asian 
countries could generate more consistent results than 
studies that include other populations outside of East Asia. 
At the same time, they also pointed out that there were 
examples which showed the possible ethnic differences 
among populations of East Asian countries, and emphasized 
the necessity of the investigations on comparison study 
in the East Asian region. Regulatory science plays the 
important role in the assessment of the ethnicity. Therefore, 
we have conducted the pharmacokinetics (PK) study of 
moxiÁ oxacin, simvastatin, and meloxicam using Japanese, 
Chinese, Koreans, and Caucasians populations under the 
same protocol. Although previous studies of these three 
drugs showed clear ethnic differences in the PK, our results 
which were obtained under the same protocol did not 
indicate the clear ethnic differences among four populations. 
Our research suggests that GCTs in the East Asian counties 
could highly accelerate the new drug development in East 
Asian region.5
